Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:DWTX NASDAQ:GNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.74-1.3%$0.77$0.38▼$115.57$8.61M0.711.52 million shs54,065 shsDWTXDogwood Therapeutics$4.86+0.6%$4.85$1.62▼$29.28$9.23M1.7913,646 shs7,696 shsGNPXGENPREX$0.25+19.7%$0.23$0.14▼$3.97$6.99M-0.6522.89 million shs12.35 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-1.27%-8.77%+12.55%-17.14%-98.62%DWTXDogwood Therapeutics+0.62%-1.02%+1.89%-6.18%+485,999,900.00%GNPXGENPREX+19.72%+52.41%+17.58%-20.12%-45.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.74-1.3%$0.77$0.38▼$115.57$8.61M0.711.52 million shs54,065 shsDWTXDogwood Therapeutics$4.86+0.6%$4.85$1.62▼$29.28$9.23M1.7913,646 shs7,696 shsGNPXGENPREX$0.25+19.7%$0.23$0.14▼$3.97$6.99M-0.6522.89 million shs12.35 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-1.27%-8.77%+12.55%-17.14%-98.62%DWTXDogwood Therapeutics+0.62%-1.02%+1.89%-6.18%+485,999,900.00%GNPXGENPREX+19.72%+52.41%+17.58%-20.12%-45.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0048,614.48% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00105.76% UpsideGNPXGENPREX 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AGNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$6.084.11N/AN/AN/AN/A-994.63%N/ADWTXDogwood Therapeutics-$12.35M-$18.78N/AN/AN/AN/AN/A-27.41%11/6/2025 (Estimated)GNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-809.27%-386.95%11/11/2025 (Estimated)Latest GNPX, DWTX, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GNPXGENPREX-$0.71-$0.17+$0.54-$0.17N/AN/A8/13/2025Q2 2025DWTXDogwood Therapeutics-$1.26-$1.99-$0.73-$1.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22DWTXDogwood TherapeuticsN/A7.807.80GNPXGENPREXN/A0.840.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%DWTXDogwood Therapeutics9.05%GNPXGENPREX14.05%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%DWTXDogwood Therapeutics3.90%GNPXGENPREX0.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.64 million74.37 millionNot OptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AGNPXGENPREX2033.47 million33.32 millionNo DataGNPX, DWTX, and AEON HeadlinesRecent News About These CompaniesGenprex Stockholders Approve Key Proposals at Annual MeetingSeptember 3, 2025 | theglobeandmail.comGenprex to Present and Participate at Upcoming September Investor and Industry ConferencesSeptember 2, 2025 | prnewswire.comGenprex receives notice of allowance for multiple patents for ReqorsaAugust 18, 2025 | msn.comGenprex Secures Patent Allowances for Gene TherapyAugust 18, 2025 | tipranks.comGenprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat CancersAugust 18, 2025 | prnewswire.comGenprex Issues Stockholder Letter and Provides 2025 Corporate UpdateAugust 4, 2025 | prnewswire.comGenprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo FinanceJune 27, 2025 | finance.yahoo.comGenprex reports positive results from diabetes gene therapy studyJune 25, 2025 | investing.comGenprex Announces Positive Preclinical Results for GPX-002June 24, 2025 | tipranks.comGenprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific SessionsJune 24, 2025 | prnewswire.comGenprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific SessionsJune 23, 2025 | prnewswire.comGenprex to Participate at BIO 2025 International ConventionJune 3, 2025 | prnewswire.comGenprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual MeetingMay 29, 2025 | prnewswire.comGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingMay 28, 2025 | prnewswire.comGenprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetesMay 9, 2025 | bioworld.comBGenprex inks sponsored research agreement with the University of Pittsburgh to study diabetes gene therapy in Type 1 and Type 2 diabetesMay 8, 2025 | pharmabiz.comPGenprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 DiabetesMay 7, 2025 | prnewswire.comGenprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of GlioblastomaMay 6, 2025 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual MeetingApril 30, 2025 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingApril 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, DWTX, and AEON Company DescriptionsAEON Biopharma NASDAQ:AEON$0.74 -0.01 (-1.27%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$0.74 +0.01 (+0.68%) As of 09/10/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Dogwood Therapeutics NASDAQ:DWTX$4.86 +0.03 (+0.62%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$4.86 0.00 (-0.10%) As of 09/10/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.GENPREX NASDAQ:GNPX$0.25 +0.04 (+19.72%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$0.24 -0.01 (-4.84%) As of 09/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
